ImaginAb, Inc.

LOS ANGELES, CA, USA I May 18, 2023 I ImaginAb, Inc., a global biotechnology company focused on the development of radiopharmaceuticals for the diagnosis and treatment of cancer, today announced lead selection and progression to IND-enabling studies of IAB56, a minibody designed to target the αvβ6 integrin for use as Lu-177 radiopharmaceutical therapy in solid tumors. In parallel, the DLL3 targeting program, IAB57, will further assess several leads in the coming quarter prior to initiation of IND-enabling studies later in 2023. ImaginAb's discovery team developed IAB56 and IAB57 at its Los Angeles R&D site via screening and selection of high affinity minibodies and cys-dibodies with demonstrated therapeutic efficacy in preclinical models. The αvβ6 integrin is a pan-cancer antigen implicated in a broad range of solid tumors including ovarian, pancreatic, breast, oral and liver cancer amongst others. The target shows expression which is highly specific to malignant diseases with very little or no expression in healthy tissues, making it an attractive candidate for targeted radiotherapy of solid cancers. Delta-like ligand 3 (DLL3) is highly selective for SCLC and neuroendocrine tumors, with minimal to no expression in healthy tissues. Given the rapid recurrence of SCLC following existing therapeutic option, there remains a significant need to improve prognosis for patients suffering from this disease. Ian Wilson, Chief Executive Officer of ImaginAb, said: "The ImaginAb team has experience in the discovery, development, and manufacture of radiopharmaceuticals. Focusing our discovery team on the identification and progression of new radiopharmaceutical therapy agents based on our proprietary platform of biologics was a natural step for ImaginAb. We are excited to announce these new developments and look forward to sharing news on these and other candidate molecules as new milestones are met." About ImaginAb ImaginAb, Inc. is a biotechnology company focused on developing radiopharmaceutical imaging and therapeutic agents. ImaginAb engineer's antibody fragments called minibodies and cys-diabodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert. ImaginAb is advancing a pipeline of minibodies against both oncology and immunology targets. The Company is backed by top tier venture capital firms and strategic corporate firms including Adage Capital Partners, the Cycad Group, Norgine Ventures, Innoviva, Jim Pallotta of the Raptor Group, the Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. ImaginAb's vision is to transform patient care, and help people live better and healthier lives. For more information visit www.imaginab.com . SOURCE: ImaginAb

IAB56 RPT agent is designed to target integrin αvβ6, a receptor over-expressed in a broad range of solid cancers underserved by current cancer therapies. IAB57 RPT agent is designed to target DLL3, a target over-expressed in cancer tissues and relevant in several cancers, most notably Small-Cell Lung Cancer (SCLC) LOS ANGELES, May 18, 2023 /PRNewswire/ -- ImaginAb, Inc., a global biotechnology company focused on the development of radiopharmaceuticals for the diagnosis and treatment of cancer, today announced lead selection and progression to IND-enabling studies of IAB56, a minibody designed to target the αvβ6 integrin for use as Lu-177 radiopharmaceutical therapy in solid tumors. In parallel, the DLL3 targeting program, IAB57, will further assess several leads in the coming quarter prior to initiation of IND-enabling studies later in 2023. ImaginAb's discovery team developed IAB56 and IAB57 at its Los Angeles R&D site via screening and selection of high affinity minibodies and cys-dibodies with demonstrated therapeutic efficacy in preclinical models. The αvβ6 integrin is a pan-cancer antigen implicated in a broad range of solid tumors including ovarian, pancreatic, breast, oral and liver cancer amongst others. The target shows expression which is highly specific to malignant diseases with very little or no expression in healthy tissues, making it an attractive candidate for targeted radiotherapy of solid cancers. Delta-like ligand 3 (DLL3) is highly selective for SCLC and neuroendocrine tumors, with minimal to no expression in healthy tissues. Given the rapid recurrence of SCLC following existing therapeutic option, there remains a significant need to improve prognosis for patients suffering from this disease. Ian Wilson, Chief Executive Officer of ImaginAb, said: "The ImaginAb team has experience in the discovery, development, and manufacture of radiopharmaceuticals. Focusing our discovery team on the identification and progression of new radiopharmaceutical therapy agents based on our proprietary platform of biologics was a natural step for ImaginAb. We are excited to announce these new developments and look forward to sharing news on these and other candidate molecules as new milestones are met." About ImaginAb ImaginAb, Inc. is a biotechnology company focused on developing radiopharmaceutical imaging and therapeutic agents. ImaginAb engineer's antibody fragments called minibodies and cys-diabodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert. ImaginAb is advancing a pipeline of minibodies against both oncology and immunology targets. The Company is backed by top tier venture capital firms and strategic corporate firms including Adage Capital Partners, the Cycad Group, Norgine Ventures, Innoviva, Jim Pallotta of the Raptor Group, the Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. ImaginAb's vision is to transform patient care, and help people live better and healthier lives. For more information visit . Logo - SOURCE ImaginAb, Inc.

This ground-breaking collaboration will enhance accuracy and efficiency of immunotherapy response for improved patient outcomes LOS ANGELES and VALENCIA, Spain, May 2, 2023 /PRNewswire/ -- ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical therapies (RPT), and Quibim, a global company born with the ambition of transforming imaging data into actionable predictions, are pleased to announce their new collaboration. Together, the two partners aim to revolutionize immunotherapy treatment planning by combining ImaginAb's investigational CD8 ImmunoPET technology with Quibim's cutting-edge image processing technology. Immunotherapy has shown remarkable promise in treating cancer and other diseases, but accurately predicting the efficacy of these treatments remains a challenge. CD8 ImmunoPET™ is an 89Zr-labeled minibody that has been designed to bind to the CD8 receptor on human T cells for quantitative, non-invasive PET imaging. This method is currently being researched to determine whether it may be used to assess the immune status of a patient, to measure the efficacy of immunotherapies, and to predict patient outcomes. As part of this collaboration, Quibim will develop an imaging-based algorithm to interpret CD8 ImmunoPET™ PET/CT exams, with the aim of quantitatively assessing the efficacy of the 89Zr-labeled minibody in targeting the CD8 receptor in the tumor microenvironment. The algorithm will use advanced image processing techniques to extract quantitative measures of tracer uptake in the tumor and surrounding tissues, enabling accurate assessment of the binding efficacy of the minibody to CD8 receptors. The resulting quantitative data will provide valuable insights into the minibody's biodistribution and targeting specificity to inform future clinical development of the imaging agent and its potential therapeutic application. Ian Wilson, Chief Executive Officer of ImaginAb, said: "This partnership presents a unique opportunity to broaden the potential applicability of CD8 ImmunoPET by incorporating advanced image processing techniques into image interpretation. We look forward to working together with Quibim to deepen our understanding of immune imaging with the aim of ultimately improving patient care." Dr. Ángel Alberich, CEO of Quibim, said: "We are thrilled to partner with ImaginAb in this ground-breaking effort to advance in the quantitative assessment of novel radiotracers' efficacy in PET/CT exams. Together, we aim to make a real difference in the lives of patients by improving the accuracy and efficiency of immunotherapy prediction through imaging-based models." Through this collaboration, ImaginAb and Quibim are poised to make significant contributions to the field of immunotherapy with the goal of improving the lives of countless patients. Stay tuned for updates on our progress and breakthroughs. About ImaginAb A clinical stage, revenue-generating global biotechnology company developing next-generation imaging agents and radiopharmaceutical therapy products through its proprietary minibody and cys-diabody platforms. The lead candidate, CD8 ImmunoPET™, is currently in Phase II clinical trials and has been licensed by pharmaceutical and biotech companies for use in immunotherapy clinical trials. For more information, visit About Quibim Quibim, with offices in New York (United States), Cambridge (UK) and Valencia, Madrid and Barcelona (Spain), was born from the ambition of transforming imaging into a catalyst for precision health. This is done designing pioneering tools that unlock imaging data to improve patient outcomes. The company is specialized in the development of AI models created by the use of real-world evidence (RWE) projects and biopharma partners to extract new insights from images; thereby developing novel quantitative imaging biomarkers to deeply analyze disease mechanisms, advance drug development, and monitor treatment progress using a whole-body approach. Quibim leads RWE studies with 10M+ de-identified research imaging registries from 50.000+ oncology patients. For more information, visit SOURCE ImaginAb, Inc.